Literature DB >> 12416253

Exercise, cachexia, and cancer therapy: a molecular rationale.

C Murray Ardies1.   

Abstract

Evidence from recent publications indicates that repeated exercise may enhance the quality of life of cancer patients. The lack of reported negative effects and the consistency of the observed benefits lead one to conclude that physical exercise may provide a low-risk therapy that can improve patients' capacity to perform activities of daily living and improve their quality of life. Repeated physical activity may attenuate the adverse effects of cancer therapy, prevent or reverse cachexia, and reduce risk for a second cancer through suppression of inflammatory responses or enhancement of insulin sensitivity, rates of protein synthesis, and anti-oxidant and phase II enzyme activities. These results most likely come about through the ability of physical exercise to attenuate a chronic inflammatory signaling process and to transiently activate the mitogen-activated protein kinase, c-Jun NH2-terminal kinase, c-Jun NH2-terminal kinase-mitogen-activated protein kinase, and nuclear factor-kappa B pathways and through its ability to enhance insulin sensitivity. Expanded molecular-based research into these areas may provide new insights into the biological mechanisms associated with cancer rehabilitation and endogenous risk.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12416253     DOI: 10.1207/S15327914NC422_1

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  12 in total

1.  Nutritional status of cancer patients and its relationship to function in an inpatient rehabilitation setting.

Authors:  Ying Guo; J Lynn Palmer; Guddi Kaur; Susan Hainley; Beth Young; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2004-12-03       Impact factor: 3.603

Review 2.  Cancer cachexia, mechanism and treatment.

Authors:  Tomoyoshi Aoyagi; Krista P Terracina; Ali Raza; Hisahiro Matsubara; Kazuaki Takabe
Journal:  World J Gastrointest Oncol       Date:  2015-04-15

3.  Activity level, apoptosis, and development of cachexia in Apc(Min/+) mice.

Authors:  Kristen A Baltgalvis; Franklin G Berger; Maria Marjorette O Peña; J Mark Davis; James P White; James A Carson
Journal:  J Appl Physiol (1985)       Date:  2010-07-22

4.  Exercise and Cancer Treatment Symptoms in 408 Newly Diagnosed Older Cancer Patients.

Authors:  Lisa K Sprod; Supriya G Mohile; Wendy Demark-Wahnefried; Michelle C Janelsins; Luke J Peppone; Gary R Morrow; Raymond Lord; Howard Gross; Karen M Mustian
Journal:  J Geriatr Oncol       Date:  2012-01-27       Impact factor: 3.599

Review 5.  Delivering care to long-term adult survivors of hematopoietic cell transplantation.

Authors:  Karen L Syrjala; Paul J Martin; Stephanie J Lee
Journal:  J Clin Oncol       Date:  2012-09-24       Impact factor: 44.544

6.  Muscle wasting and interleukin-6-induced atrogin-I expression in the cachectic Apc ( Min/+ ) mouse.

Authors:  Kristen A Baltgalvis; Franklin G Berger; Maria Marjorette O Peña; J Mark Davis; James P White; James A Carson
Journal:  Pflugers Arch       Date:  2008-08-19       Impact factor: 3.657

7.  Premature Atherosclerotic Cardiovascular Disease in Childhood Cancer Survivors.

Authors:  Charles W Shepard; Julia Steinberger
Journal:  Prog Pediatr Cardiol       Date:  2015-11-17

8.  Cancer cachexia prevention via physical exercise: molecular mechanisms.

Authors:  Douglas W Gould; Ian Lahart; Amtul R Carmichael; Yiannis Koutedakis; George S Metsios
Journal:  J Cachexia Sarcopenia Muscle       Date:  2012-12-13       Impact factor: 12.910

Review 9.  Rehabilitation and quality-of-life issues in patients with extremity soft tissue sarcoma.

Authors:  Janet A Parsons; Aileen M Davis
Journal:  Curr Treat Options Oncol       Date:  2004-12

Review 10.  Cancer cachexia--pathophysiology and management.

Authors:  Hajime Suzuki; Akihiro Asakawa; Haruka Amitani; Norifumi Nakamura; Akio Inui
Journal:  J Gastroenterol       Date:  2013-03-20       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.